- Letter to the Editor
- Open Access
STAT3 mutations are frequent in T-cell large granular lymphocytic leukemia with pure red cell aplasia
Journal of Hematology & Oncology volume 6, Article number: 82 (2013)
T-cell large granular lymphocytic leukemia (T-LGLL) is a rare lymphoproliferative disorder and can cooccur in the context of pure red cell aplasia (PRCA). The aim of the current study was to analyze the signal transducer and activator of transcription 3 (STAT3) mutation status and its clinical significance in T-LGLL. We found STAT3 mutations in 21.4% of patients with T-LGLL. High β2-MG (β2-microglobulin) levels (P = 0.005), neutropenia (P = 0.018) and PRCA (P = 0.001) all displayed a significant association with STAT3 mutations. In univariate analysis, treatment-free survival (TFS) was affected by STAT3 mutation status (P = 0.008) and β2-MG (P = 0.006). Our results demonstrate the remarkable correlation of STAT3 mutation with PRCA, neutropenia and β2-MG.
To the editor
T-cell large granular lymphocytic leukemia (T-LGLL) is a rare lymphoproliferative disorder and can cooccur in the context of pure red cell aplasia (PRCA) [1–3]. Recently, recurrent somatic mutations in the Src homology domain of the signal transducer and activator of transcription 3 (STAT3) gene have been identified to have a high frequency of 40%  and 33%  in T-LGLL. To analyze the STAT3 mutation status and its clinical significance, we investigated STAT3 mutations in 28 consecutive patients with newly diagnosed T-LGLL who were recruited between January 2007 and January 2013. The diagnosis of T-LGLL was based on the WHO criteria . The diagnosis of PRCA was defined according to the previous report .
For STAT3 mutation screening, genes of exons 20 and 21 of STAT3 were amplified by PCR and sequenced. Five different mutations (Y640F, D661Y, E616V, V671F, S614R) were observed, and two mutations, E616V and V671F, had not been previously reported. STAT3 is an oncogene, and its activation plays a key role in cell signaling in many types of cancer . In our study, all mutations were heterozygous and the mutational hot spot were located close to the transcriptional activation domain.
Seven patients (25%) were found to have both T-LGLL and PRCA. STAT3 mutation was more common among patients with PRCA than those without PRCA (71.4% vs.4.8%, P = 0.001). Six of 7 (85.7%) patients with PRCA were found to have elevated β2-MG (β2-microglobulin), which was significantly higher than was found in 6 of 18 (33.3%) patients without PRCA (P = 0.030, Table 1). On the other hand, patients with STAT3 mutations had presented with neutropenia more often than those without STAT3 mutations (100% vs. 40.9%, P = 0.018), and this is similar to previous studies .
Anemia, neutropenia and rheumatoid arthritis (RA) are common complications, and anemia is more common in Asian countries [8, 9]; neutropenia and RA is more common in Western countries [10, 11], but there was no patients with RA in our study. We show here that the coexistence of PRCA or neutropenia is more frequent in patients with STAT3 mutation. This observation varies from from the study of Jerez et al.  and Koskela et al. , but is consistent with the study from Japan .
TFS was defined as the period from the diagnosis date to the time of the first treatment. In our study, we observed a significant difference between patients with or without STAT3 mutations in TFS (median 6.5 months vs. 16.6 months, P = 0.008, Figure 1A), and we observed a significant difference between the high β2-MG group and the low β2-MG group in TFS (P = 0.003 Figure 1C). TFS was not related to LDH levels (Figure 1B).
To our knowledge, our study is the first report on STAT3 mutation status in patients with T-LGLL in China. Although the STAT3 mutation thus likely contributes to the pathogenesis of T-LGLL, patients without STAT3 mutations are characterized by significant heterogeneity, indicating that other mechanisms of STAT3 activation can be operative in this disease. Further studies are therefore necessary to determine other reasons to lead to the pathogenesis of T-LGLL.
T-cell large granular lymphocytic leukemia
Signal transducer and activator of transcription 3
Pure red blood cell aplasia
Absolute neutrophil count
Swerdlow SH, International Agency for Research on Cancer, World Health Organization: WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues(4th Ed). 2008, Lyon, France: International Agency for Research on Cancer
Abkowitz JL, Kadin ME, Powell JS, Adamson JW: Pure red cell aplasia: lymphocyte inhibition of erythropoiesis. Br J Hematol. 1986, 63: 59-67. 10.1111/j.1365-2141.1986.tb07495.x.
Lamy T, Loughran TP: How I treat LGL leukemia. Blood. 2011, 117: 2764-2774. 10.1182/blood-2010-07-296962.
Koskela HL, Eldfors S, Ellonen P, van Adrichem AJ, Kuusanmäki H, Andersson EI: Somatic STAT3 mutations in large granular lymphocytic leukemia. N Engl J Med. 2012, 366 (20): 1905-1913. 10.1056/NEJMoa1114885.
Jerez A, Clemente MJ, Makishima H, Koskela H, Leblanc F, Peng Ng K: STAT3 mutations unify the pathogenesis of chronic lymphoproliferative disorders of NK cells and T-cell large granular lymphocyte leukemia. Blood. 2012, 120 (15): 3048-3057. 10.1182/blood-2012-06-435297.
Kwong YL, Wong KF, Liang RH, Chu YC, Chan LC, Chan TK: Pure red cell aplasia: clinical features and treatment results in 16 cases. Ann Hematol. 1996, 72: 137-140. 10.1007/s002770050151.
Bromberg JF, Wrzeszczynska MH, Devgan G, Zhao Y, Pestell RG, Albanese C: Stat3 as an oncogene. Cell. 1999, 98: 295-303. 10.1016/S0092-8674(00)81959-5.
Kwong YL, Au WY, Leung AY, Tse EW: T-cell large granu1ar lymphocyte leukemia: an Asian perspective. Ann Hematol. 2010, 89 (4): 331-339. 10.1007/s00277-009-0895-3.
Kawahara S, Sasaki M, Isobe Y, Ando J, Noguchi M, Koike M: Clinical analysis of 52 patients with granular lymphocyte proliferative disorder (GLPD) showed frequent anemia in indolent T-cell GLPD in Japan. Eur J Haematol. 2009, 82: 308-314. 10.1111/j.1600-0609.2009.01213.x.
Burks EJ, Loughran TP: Pathogenesis of neutropenia in large granular lymphocyte leukemia and Felty syndrome. Blood Rev. 2006, 20: 245-266. 10.1016/j.blre.2006.01.003.
Sokol L, Loughran TP: Large granular lymphocyte leukemia. Oncologist. 2006, 11 (3): 263-273. 10.1634/theoncologist.11-3-263.
Sekiguchi N, Matsuda K, Momose K, Makishima H, Ito T, Ishida F: STAT3 gene mutations and the association with pure red cell aplasia in large granular lymphocyte leukemia [abstract 2668]. 2012, 54TH ASH® Annual Meeting and Exposition,
This study was supported by the National Natural Science Foundation of China (Grant Nos. 30871104, 30971296, 81170485, 81170488), the Natural Science Foundation of Jiangsu Province (Grant No. BK2010584), Key Projects of Health Department of Jiangsu Province (Grant No. K201108), Jiangsu Province’s Medical Elite Program (Grant No. RC2011169), National Public Health Grand Research Foundation (No.201202017) , Project Funded by the Priority Academic Program Development of Jiangsu Higher Education Institute (No. JX10231801), the Program for Development of Innovative Research Teams in the First Affiliated Hospital of Nanjing Medical University, and Project of National Key Clinical Specialty.
The authors declare that they have no competing interests.
ZYQ performed the laboratory work for this study and wrote the manuscript; LF and LW provided material and clinical information; CQ and YJW designed the experiments; JFZ analyzed data; WX and JYL performed statistical analysis and wrote the manuscript. All authors have approved the final version of the manuscript.
Authors’ original submitted files for images
Below are the links to the authors’ original submitted files for images.
About this article
Cite this article
Qiu, Z., Fan, L., Wang, L. et al. STAT3 mutations are frequent in T-cell large granular lymphocytic leukemia with pure red cell aplasia. J Hematol Oncol 6, 82 (2013). https://doi.org/10.1186/1756-8722-6-82